stockrow
Monday 9 November 2026
Export CAMP’s income statement to Excel — free account
CAMP4 Therapeutics Corporation
CAMPCAMP4 Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, up 436.5% from fiscal 2024.
- Revenue
- +138.9%
- EPS
- +32.7%
- Free cash flow
- +20.4%
Quarter to September 2026, against a year earlier
4.06
0.34
+9.14%
Follow CAMP
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(145.07%) | (209.28%) | (545.85%) | (146.12%) | |
| (82.00%) | (102.60%) | (148.23%) | (109.89%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(79.67%) | (98.63%) | (147.45%) | (112.47%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.55) | (0.45) | (0.50) | (0.33) | |
Free Cash Flow |
(29.80) | (26.25) | (28.68) | (26.37) | |
Capital Expenditures |
(0.24) | — | (0.09) | (0.83) | |
| Other line items | |||||
Cash ROIC |
(18.79%) | (20.06%) | (33.19%) | (11.35%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,092.11% | 971.43% | 917.69% | 766.32% | |
Selling, General and Administrative Expense of Revenue |
496.20% | 451.19% | 424.81% | 334.74% | |
Share Based Compensation of Revenue |
114.29% | 117.16% | 131.36% | 123.65% | |
Operating CF/Net income |
0.37 | 0.30 | 0.27 | 0.21 | |
Depreciation/Fixed assets |
0.70 | 0.90 | 0.99 | 0.00 | |
Capex/Depreciation |
(0.15) | 0.00 | (0.05) | (0.43) | |
Revenue per Share |
0.06 | 0.07 | 0.07 | 0.07 | |
Operating CF per Share |
(0.55) | (0.45) | (0.49) | (0.32) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.07 | 0.00 | 0.02 | 0.16 |
Columns are period end dates · fundamentals updated 5 Nov 2026